Monte Rosa Therapeutics (GLUE) Non Operating Investment Income (2023)
Monte Rosa Therapeutics' (GLUE) quarterly Non Operating Investment Income came in at -$131000.0 in Q1 2023.
Monte Rosa Therapeutics (GLUE) Non Operating Investment Income (2023) Analysis & Trends
Monte Rosa Therapeutics' Non Operating Investment Income history runs 1 years deep, the most recent figure standing at -$131000.0 for Q1 2023.
- On a quarterly basis, Non Operating Investment Income changed N/A year-over-year to -$131000.0 in Q1 2023; TTM through Dec 2023 was -$131000.0, a N/A change from a year earlier, with the FY2023 full-year figure at -$131000.0, changed N/A from the prior year.
- Non Operating Investment Income held at -$131000.0 in Q1 2023 per GLUE's latest filing.
- Across five years, Non Operating Investment Income topped out at -$131000.0 in Q1 2023 and bottomed at -$131000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Monte Rosa Therapeutics | 2.29 Bn | 1.61 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -131,000.00 |
| Mar 31, 2023 | -131,000.00 |